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Introduction: Triple negative breast cancer (TNBC) is a heterogeneous collection of biologically diverse cancers,
which contributes to variable clinical outcomes. Previously, we identified a TNBC subtype that has a luminal
phenotype and expresses the androgen receptor (AR+). TNBC cells derived from these luminal AR + tumors have
high frequency phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutations. The
purpose of this study was to determine if targeting phosphoinositide 3-kinase (PI3K) alone or in combination with
an AR antagonist is effective in AR + TNBC.
Methods: We determined the frequency of activating PIK3CA mutations in AR + and AR- TNBC clinical cases.
Using AR + TNBC cell line and xenograft models we evaluated the effectiveness of PI3K inhibitors, used alone or in
combination with an AR antagonist, on tumor cell growth and viability.
Results: PIK3CA kinase mutations were highly clonal, more frequent in AR + vs. AR- TNBC (40% vs. 4%), and
often associated with concurrent amplification of the PIK3CA locus. PI3K/mTOR inhibitors had an additive growth
inhibitory effect when combined with genetic or pharmacological AR targeting in AR + TNBC cells. We also analyzed
the combination of bicalutamide +/- the pan-PI3K inhibitor GDC-0941 or the dual PI3K/mTOR inhibitor GDC-0980 in
xenograft tumor studies and observed additive effects.
Conclusions: While approximately one third of TNBC patients respond to neoadjuvant/adjuvant chemotherapy,
recent studies have shown that patients with AR + TNBC are far less likely to benefit from the current standard of
care chemotherapy regimens and novel targeted approaches need to be investigated. In this study, we show that
activating PIK3CA mutations are enriched in AR + TNBC; and, we show that the growth and viability of AR + TNBC
cell line models is significantly reduced after treatment with PI3K inhibitors used in combination with an AR
antagonist. These results provide rationale for pre-selection of TNBC patients with a biomarker (AR expression) to
investigate the use of AR antagonists in combination with PI3K/mTOR inhibitors.* Correspondence: j.pietenpol@vanderbilt.edu
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Over the past decade, the term triple-negative breast
cancer (TNBC) has been used to classify tumors that
lack detectable expression of the estrogen receptor (ER)
and progesterone receptor (PR) and amplification of
human epithelial growth factor receptor 2 (HER2). TNBC
tumors are generally more aggressive than their ER +
counterparts, with higher rates of relapse in the early
stages and decreased overall survival in the metastatic set-
ting [1,2]. Although successful targeted therapies exist for
ER + and HER2-amplified breast cancer, TNBC has been
particularly difficult to treat given the biology of the
disease has not been well understood. TNBC represents
multiple independent subtypes likely requiring different
therapeutic approaches, and until recently, targets for
therapeutic intervention have remained elusive [3].
Current standard of care for TNBC consists of treating
patients with a combination of anthracyclines and
taxanes and is based on the positive results of numerous
trials showing that chemotherapy combinations with
these drugs, in the neo-adjuvant setting in particular,
can give significant increased clinical response rates [4].
Nonetheless, there is a major need for new therapeutic
options for patients suffering from TNBC.
Investigators exploring the genomic architecture of
TNBCs discovered a spectrum of somatic mutations;
however, only a few loci are recurrently mutated with
significant frequency [5,6]. TP53 mutations are the most
frequent clonal events (62%) followed by mutations in
PIK3CA (10.2%), the gene that encodes the p110α
catalytic subunit of phosphatidylinositol-3 kinase (PI3K).
Through integrated analyses of numerous world-wide gene
expression (GE) datasets and a panel of TNBC lines,
our laboratory provided insight into the heterogeneity
of TNBC disease by identifying distinct molecular
subtypes displaying unique biology that includes two
basal-like (BL1 and BL2), an immunomodulatory (IM), a
mesenchymal (M), a mesenchymal stem-like (MSL), and a
luminal androgen receptor (LAR) subtype [3]. Of note, we
demonstrated that LAR cells are in part dependent on AR
signaling as siRNA-mediated AR knockdown or pharma-
cological inhibition of AR by bicalutamide (CDX) greatly
decreases cell viability and tumor growth [3]. Also, we ob-
served that all commercially available AR-positive (AR+)
TNBC cell lines contain the PIK3CA mutation (H1047R)
and are highly sensitive to the PI3K/mTOR inhibitor
NVP-BEZ235 [3]. Collectively, these findings are consist-
ent with observations that hormonally responsive cancers,
such as those expressing ER [7] and AR [5,8] are more
likely to acquire PIK3CA mutations, thus prompting the
experiments and discoveries reported herein.
With the goal of generating pre-clinical data that could
be advanced to clinical trial design for the various sub-
types of TNBC, we further investigated the molecularfeatures of the AR + TNBC subtype, LAR. First, we dis-
covered that PIK3CA kinase domain mutations are a
frequent event in AR + TNBC clinical cases. We found
that genetic or pharmacological targeting of AR in LAR
cells increases the growth inhibitory activity of PI3K
inhibitors. Further, we explored the combination of AR
antagonism and PI3K inhibition and found an additive
or synergistic effect on AR + TNBC cell growth. Given
that AR protein expression is a reliable surrogate of LAR
gene expression within TNBC, our preclinical findings
provide a strong rationale for the use of AR as a bio-
marker for the selection of TNBC patients for clinical
trials, which would investigate the efficacy of therapeutic
combinations that simultaneously target AR and PI3K.
Methods
Acquisition of tumor tissue for this study
After the Vanderbilt University Institutional Review
Board (IRB) approved the project protocol and waived
the need for patient consent, de-identified TNBC tumor
tissues were obtained. ER, PR and HER2 status as deter-
mined at the time of clinical evaluation was available for
all specimens and was retested for the purposes of this
project (see Immunostaining section below). Both frozen
and formalin-fixed paraffin-embedded (FFPE) tissue sam-
ples were obtained. In addition, surgically resected tumor
samples were obtained from patients with TNBC diag-
nosed and treated with neoadjuvant chemotherapy at the
Instituto Nacional de Enfermedades Neoplásicas in Lima,
Perú. Clinical and pathological data were retrieved from
medical records under an institutionally approved proto-
col (INEN 10-018) and de-identified prior to distribution
to Vanderbilt University Medical Center. Tumors were
determined as triple-negative if they were negative for ER,
PR and HER2 overexpression measured by immunohisto-
chemistry (IHC).
Immunostaining
Both frozen sections and FFPE tissue were used for immu-
nohistochemical studies. For FFPE sections, antigen re-
trieval for both ER and PR were performed using citrate
buffer (pH 6) in a decloaking chamber (Biocare Medical,
Concord, CA, USA). ER (6 F11, Vector Labs, Burlingame,
CA) PR (PgR636; DAKO, Carpinteria, CA) and HER2 (#2242;
Cell Signaling, Danvers, MA) antibodies were utilized at
1:200, 1:50, and 1:200 dilutions, respectively. Antigen retrieval
was omitted for the frozen tissues and the antibody dilu-
tions were decreased to 1:400, 1:100 and 1:400 respect-
ively. Visualization for both antibodies was performed
using the Envision Detection System (DAKO) and 3,3-
diaminobenzidine (DAB) (DAKO) as the chromogen. The
percentage of invasive tumor cells with nuclear ER and
PR staining and the average intensity of all positively
staining tumor cells in the section were manually counted
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ety of Clinical Oncology (CAP/ASCO) guidelines [9]. The
percentage of invasive tumor cells with membranous
HER2 staining at the highest intensity level was manually
assessed and recorded as per CAP/ASCO guidelines [10].
For FFPE sections, antigen retrieval for AR (DAKO,
clone AR411) was performed using citrate buffer pH 6.0
in a decloaking chamber followed by 1-h incubation with
antibody at room temperature at a dilution of 1:300.
Antigen retrieval for p-AKT p473 (Cell Signaling) was
performed using Trilogy buffer pH 6.0 (Cell Marque) in
a decloaking chamber (Biocare Medical) followed by
overnight incubation at 4° at a 1:25 antibody dilution.
Antigen retrieval was omitted for the frozen tissues and
the antibody dilutions were decreased to 1:600 and 1:30,
respectively. To reduce the possibility of false nega-
tives, tumors were determined to be AR + when >30%
of the cells showed nuclear positivity of any detectable
intensity level.
Fluorescence in situ hybridization for HER2
Both frozen sections and FFPE tissue were used for fluor-
escence in situ hybridization (FISH). FISH for detection of
possible amplification of HER2 was performed using the
PathVysion HER-2 DNA Probe Kit (PathVysion Kit,
Abbott Molecular, Des Planes, IL, USA) utilizing the Vysis
LSI HER2/neu 17q11.2-12 SpectrumOrange™ and Vysis
CEP 17 17p11.1-q11.1 SpectrumGreen Alpha Satellite
DNA probes for cases with 2+ or 3+ expression by IHC.
Images were visualized on a Fluorescence Olympus BX60
Microscope and analyzed using the Genus™ for Genetic
Image Analysis software, version 3.6. The ratio of HER2 to
CEP 17 signals was recorded and reported as an average
ratio as per CAP/ASCO guidelines [10].
PIK3CA mutation evaluation
Sanger sequencing was used to detect mutations in exons 9
and 20 of PIK3CA of PCR-amplified regions from genomic
DNA. Genomic DNA was isolated from FFPE tissues of 25
AR + and 25 AR- TNBC tumors (QiaAmp FFPE, Qiagen,
Valencia, CA). Genomic DNA (20 ng) was PCR-amplified
in exons 9 (168 bp fragment) and 20 (159 bp fragment)
using the following amplification primers: PIK3CA_ex9_F:
GTTTTCCCAGTCACGACGGAAAATGACAAAGAACA
GC; PIK3CA_ex9_R: CAGGAAACAGCTATGACCTGAG




Subtyping TNBC cases and validating PIK3CA mutations
in the The Cancer Genome Atlas (TCGA)
RNA-seq (lvl 3), somatic mutations (lvl3) and reverse-
phase protein array (RPPA, lvl3) data for breast cancerwere downloaded from TGCA (tcga-data.nci.nih.gov/).
RNA-seq data (RPKM) was combined and molecularly
subtyped using the online TNBCtype software according
to published methods [11]. After removal of potential
ER + samples, 102 TNBC samples were identified
and assigned a molecular subtype, which included four
ER + samples by IHC that were called ER- by RNA
(Additional file 1: Table S1). Differences in RNA, protein
and mutations were evaluated by Student’s t-test.Reverse-phase protein array on TNBC cell lines
Tumor or cell lysates were two-fold serial diluted for five
dilutions (from undiluted to 1:16 dilution) and arrayed
on a nitrocellulose-coated slide in 11 × 11 format. Sam-
ples were probed with antibodies by the Catalyzed Signal
Amplification (DAKO, Carpinteria, CA) amplification
approach and visualized by DAB colorimetric reaction.
Slides were scanned and density quantified by MicroVigene.
Relative protein levels for each sample were determined
by interpolation of each dilution curve from the standard
curve (supercurve) of the slide (antibody) as previously
described [12]. These values were log2-transformed and
normalized for protein loading by linear transformation.
Linear normalized data were then median-centered for
heatmap comparisons.Cell proliferation/viability assays and inhibitory
concentration of 50% (EC50) determination
All cell lines were maintained in culture as previously
described [3]. To evaluate response to dihydrotestoster-
one (DHT) cells were grown in charcoal-stripped (CS)
media for two days prior to plating in 96-well tissue
culture dishes. Media were then changed to fresh CS-
media alone or increasing doses of DHT and viability
determined by measuring fluorescent intensity after
metabolic reduction of AlamarBlue five days later. For
drug treatments, breast cancer cell lines and HMECs
were seeded (3,000 to 10,000 cells) in quadruplicate
wells in 96-well plates. After attachment, media was
replaced with either fresh media (control) or media con-
taining half-log serial dilutions of the following drugs:
GDC-0941 (10 nM-3000 nM), GDC0980 (1 nM-300 nM),
BKM120 (10 nM-3000 nM) and NVP-BEZ235 (1 nM-300
nM) purchased from Selleck Chemicals (Houston, TX) or
in combination with bicalutamide (CDX) (Sigma, St.
Louis, MO). Viability was determined by measuring fluor-
escent intensity after metabolic reduction of AlamarBlue
in the presence/absence of drug incubation for 72 h. Via-
bility assays were performed in triplicate and replicates
were normalized to untreated wells. EC50 values were de-
termined after double log-transformation of dose response
curves as previously described [3].
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We transfected 293FT cells with Lipofectamine 2000
(Invitrogen, Grand Island, NY) the packaging vectors
pPAX2 and pMD2.g (Addgene, Cambridge, MA) along
with pLKO.1-puro Misson shRNA constructs (Sigma)
targeting AR or a non-targeting control. Viral media
were harvested 48 h post transfection and added to
target cells along with polybrene (10 μg/mL). At 72 h
post infection MDA-MB-453 (8,000 cells/well), CAL-148
(5,000 cells/well), SUM-185 (8,000 cells/well) and MFM-
223 (7,000 cells/well) were seeded in quadruplicate
in 96-well plates. After attachment, media were replaced
with fresh media (control) or media containing half-log
dilutions of (BKM120 10 to 3,000 nM, GDC-0941 10 to
3,000 nM, NVP-BEZ235 1 to 300 nM and GDC0980
3 to 1,000 nM). After incubation in drug for 72 h,
viability was measured with AlamarBlue as previously
described [3].
Forced suspension viability assay
CAL-148, MFM-223, MDA-MB-453 and SUM-185
cells were plated (10,000 cells/well) in quadruplicate into
96-well plates coated with 0.9% agarose diluted in corre-
sponding media. Following five days of growth, cells
were treated with increasing half-log concentrations of
GDC-0941 (10 to 3,000 nM), GDC0980 (1 nM to 300
nM), BKM120 (10 nM to 3,000 nM) and NVP-BEZ235
(1 nM to 300 nM) alone or in combination with 25 μM
CDX for an additional 72 h, after which cells were imaged
and viability determined by AlamarBlue.
Immunoblotting
Cells were trypsinized, lysed and protein concentration
was determined by immunoblot as previously described
(12) with the following antibodies; AR polyclonal anti-
body, (SC-N20, Santa Cruz Biotechnology, Dallas, Texas),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
(EMD Millipore, Billerica, MA) and the following anti-
bodies from Cell Signaling pS6-Ser235/236 (#4856), S6
(#2317), p-AKT-S473 (#9271), and AKT (#9272).
Xenograft tumor studies
Five-week-old female athymic nude Foxn1nu mice (Harlan,
Indianapolis, IN) were injected (subcutaneously) with
either approximately 4 × 106 (CAL-148) cells suspended in
media (200 μL) or approximately 10 × 106 (MDA-MB-
453) cells suspended in 100 μL media and 100 μL matrigel
into each flank using a 22-gauge needle. Once tumors
reached a volume of 25 to 50 mm3, mice were randomly
assigned to treatment or vehicle arms. Treatments in-
cluded CDX per os (p.o.) (100 mg/kg/d) or GDC0980 per
os (p.o.) (7.5 mg/kg/d) in 5% dimethyl sulfoxide (DMSO),
0.5% carboxymethyl cellulose (MCT) or NVP-BEZ235 per
os (p.o.) (50 mg/kg/d) in 0.5% MCT as well as thecombination of CDX and either GDC-0980 or NVP-
BEZ235 according to the above concentrations. Tumor di-
ameters were serially measured at the indicated times with
digital calipers and tumor volumes were calculated as
width2 × length/2. All studies were assessed for the ethical
use and treatment of animals and received ethical approval
by the Institutional Animal Care and Use Committee of
Vanderbilt University.
Results
AR + TNBCs are enriched for PIK3CA activating mutations
Previously we demonstrated high frequency of PIK3CA
mutations in AR + TNBC cell lines [3]. To determine if
PIK3CA mutations frequently arise in AR + TNBC, we
performed Sanger sequencing on 26 AR + and 26 AR-
TNBC clinical cases. We sequenced PCR-amplified
regions from exons 9 and 20, the region of the gene har-
boring the most frequently occurring activating mutations.
Consistent with our observations and ruling out in vitro
selection for PIK3CA mutations in AR + LAR cell lines,
we found that PIK3CA mutations were significantly
(P <0.002) enriched in AR + (10/25, 40%) versus AR-
TNBCs (1/25, 4%) (Figure 1A). Nearly all of the detected
mutations occurred in the kinase domain (H1047R/L;
9 of 10) with only one occurring at E545K in the helical
domain.
Validation of PIK3CA mutations in AR-expressing TNBC
To verify the high frequency of PIK3CA mutations in
TNBC tumors with elevated levels of AR protein, we
analyzed the RNA-seq, DNA-seq and reverse-phase pro-
tein array (RPPA) data in TCGA breast cancer cohort
[6]. In order to remove potential false negatives for ER,
we calculated the percentile of ER gene expression for
each tumor specimen and removed tumors that displayed
ER expression above the 75th percentile of all genes.
The resulting 102 tumors were classified according to
TNBC molecular subtypes using the TNBCtype algorithm
tool (Additional file 1: Table S1) [11]. The distribution of
samples across the TNBC subtypes was similar to that
which we had previously reported [3,11], (UNS = 9 (8.8%),
BL1 = 22 (21.6%), BL2 = 8 (7.8%), IM= 18 (17.6%), M = 24
(23.5%), MSL = 8 (7.8%) and LAR =13 (12.7%); Figure 1B
and Additional file 1: Table S1). As expected, analysis
of RNA-seq data generated from the LAR subtype
samples confirmed significant levels of AR RNA (1,219
versus 101 reads per kilobase per million reads (RPKM),
P <0.0001) and protein by RPPA (0.64 versus -1.15,
P <0.0001) (Figure 1B and Additional file 1: Table S1).
PIK3CA mutations were relatively infrequent (10 of 102,
9.8%) in TNBC cases overall in TCGA dataset (Figure 1B).
However, when sorted by subtype, PIK3CA mutations
were significantly enriched among LAR TNBCs (6 of 13,
46.2%) compared to all other TNBC subtypes (4 of 89,
Figure 1 Identification of PIK3CA mutations in androgen receptor (AR) + triple-negative breast cancer (TNBC) cell lines and tumors.
(A) Table displays the frequency of PIK3CA mutations (H1047R) in 25 TNBC AR + and 25 AR- TNBC human tumors. (B) Panel displays the TNBC
molecular subtypes of The Cancer Genome Atlas (TCGA) breast cancer tumors with corresponding heatmaps showing the relative levels of AR
RNA (RNA-seq) and AR protein (reverse-phase protein array (RPPA)). Those cases lacking protein or RNA evaluation are colored in black. The
bottom row is a color bar indicating PIK3CA mutations (red) or wild-type (black) within the TCGA TNBC cases.
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tions, consistent with our findings above (Figure 1B).
We evaluated the allele frequency of mutant and wild-
type alleles in three AR + TNBCs containing H1047R
PIK3CA. Since DNA-seq data were not available for two
samples, we determined if allele frequencies in RNA-seq
were comparable to DNA-seq from a tumor sample with
both types of data (TCGA-C8-A12L). DNA-seq and
RNA-seq (86% versus 77%) produced similar mutant al-
lele frequencies, suggesting that RNA-seq could provide
a reliable estimate of allele frequency (Additional file 2:
Figure S1A). All three AR+/PIK3CA mutant TNBCs
demonstrated a high allele frequency for the H1047R
mutation (77%, 67%, and 53%), greater than the expected
frequency for a heterozygous mutation (in a tumor cellu-
larity >80%), suggesting that either the other allele had
lower expression or that the mutant allele was amplified
(Additional file 2: Figure S1B). We further evaluated the
DNA copy number (CN) of 14 MB of DNA sequence
surrounding the PIK3CA locus. CN analysis showed that
the PIK3CA locus was amplified (1.544, 1.436, and 1.316,
log2) in AR+/PIK3CA mutant tumors, including one
tumor (TCGA-C8-A12L) with a focal amplification of only
12 genes (Additional file 3: Figure S2). The concurrent
mutation and amplification of PIK3CA frequently occur in
all of breast cancer with 42% (18 of 43) of tumors with
amplified PIK3CA also harboring a PIK3CA mutation
(Additional file 3: Figure S2).
LAR TNBC cell lines stimulated by dihydrotestosterone
have increased PI3K pathway activity and are sensitive to
PI3K/TOR pathway inhibitors
To demonstrate that AR +TNBC cell lines are responsive
ligands, we measured the proliferation of the AR-dependent
prostate cancer cell line LNCAP and AR+TNBC cell lines
five days after treatment with increasing doses ofDihydrotestosterone (DHT). Low levels of DHT (femtomo-
lar and picomolar concentrations) were sufficient to in-
crease cell number two-fold in both LNCAP and AR +
TNBC cell lines, demonstrating that proliferation of the
cell lines can be increased by AR signaling (Figure 2A).
Since the AR + TNBC cell lines have intact AR signal-
ing and PIK3CA mutations, we used RPPA to investigate
AR, PTEN, p-AKT (S473 and T308) and p-GSK3β (S21/
S9) protein levels in TNBC cell lines. We assessed PI3K
pathway activity as determined by relative levels of p-AKT
and p-GSK3β across the cell panel and, in particular in
AR-expressing, PIK3CA mutant TNBCs (Additional file 4:
Table S2). Elevated PI3K signaling correlated with PIK3CA
mutation and loss of PTEN in TNBC cell lines as evi-
denced by high expression of activated p-AKT S473
(2.18 versus -0.23, P = 0.007) and p-AKT T308 (1.45
versus -0.10, P = 0.0032), and increased levels of p-GSK3β
S9 (1.00 versus -0.26, P = 0.0094) and p-GSK3β S21/S9
(1.12 versus -0.19, P = 0.0026) (Figure 2B). Similarly,
those cell lines that are null for PTEN (BT549, CAL51,
HCC1395, HCC1806, HCC1937, HCC38, HCC70, MDA-
MB-436 and MDA-MB-468) displayed higher levels of
PI3K signaling (p-AKT S473 1.28 versus -1.28, P = 0.0001,
p-AKT T308 0.41 versus -0.53, P = 0.0018, p-GSK3β S9
0.37 versus -0.76, P = 0.0002 and p-GSK3β S21/S9 0.26
versus -0.59, P = 0.0009).
To expand on the RPPA data, we performed immuno-
blot analyses of the PI3K/mTOR pathway in four LAR cell
lines (CAL-148, MDA-MB-453, MFM-223, and SUM-185),
as well as LNCaP cells (positive control) and primary cul-
tures of human mammary epithelial cells (HMEC; negative
control)) (Figure 2C). AR was expressed in the LAR TNBC
cell lines at levels equal to or greater than LNCaP cells.
With the exception of SUM-185 cells, AR +TNBC cell
lines displayed higher levels of p-AKT (S473) and phos-
phorylated ribosomal S6 than human mammary epithelial
Figure 2 Androgen receptor (AR) + triple-negative breast cancer (TNBC) cell lines have activated PI3K signaling and respond to
dihydrotestosterone (DHT) stimulation (A) Graphs display relative viability of the prostate cancer cell line (LNCAP, red line) compared
to each of the AR + TNBC cell lines (blue line) 5 days after addition of increasing doses of DHT in charcoal-stripped media. (B) Heatmap
displays relative protein levels (reverse-phase protein array, RPPA) of AR, p-AKT (S473 and T308), p-GSK3β (S9 and S21) and PTEN across indicated
TNBC cell lines. Unsupervised hierarchical clustering was performed on PI3K pathway proteins (PTEN, p-AKT and p-GSK3β). Known PI3K pathway
aberrations are indicated in the colorbar as PTEN loss (blue) or PIK3CA mutations (red). (C) Immunoblot displays relative protein levels of AR,
p-AKT, p-S6 in AR-expressing prostate cancer (LNCaP), primary cultures of human mammary epithelial cells (HMECs) and the indicated LAR TNBC
cell lines. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serves as a loading control. (D) Immunohistochemistry of indicated proteins was
performed on cell lines to assess levels of AR and p-AKT (S473). Results are representative of three independent experiments.
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stream mTOR, respectively (Figure 2C).
To evaluate the uniformity of AR expression, we
performed IHC for AR and p-AKT (S473) on LAR cell
lines (Figure 2D). The AR-expressing cell lines displayed
differing percentages of cells positive for AR protein ex-
pression (CAL-148: approximately 60%, MDA-MB-453:
>95%, MFM-223: >95% and SUM-185: >95%). The lower
percentage of AR + cells in the CAL-148 cell line is con-
sistent with decreased levels by immunoblot analysis.
Furthermore, the IHC analysis for p-AKT had similar
trends to SUM-185 and HMECs, having low levels in
both IHC and immunoblot analysis (Figure 2D). To de-
termine if AR + cells displayed activated AKT, we per-
formed dual immunofluorescence staining for AR and
p-AKT (Additional file 5: Figures S3 and Additional file
6: Figure S4). The localization of p-AKT was primarily
cytoplasmic, however due to the cytospin preparation
and lack of adherence, localization is atypical. Regard-
less, nearly all AR + cells stained positive for p-AKT.
Since there was heterogeneity in AR expression, we per-
formed fluorescence-activated cell sorting (FACS) of AR
in the AR + cell lines. SUM-185 cells displayed the high-
est levels of AR followed by MDA-MB-453, MFM-223
and CAL-148 (Additional file 7: Figure S5A). CAL-148
cells contained distinct populations expressing low
(ARlow) and high (ARhigh) levels of AR. Sanger sequen-
cing of PIK3CA amplicons from ARlow and ARhigh
sorted-cell populations revealed similar frequencies to
mutant alleles in each population (Additional file 7:
Figure S5B), suggesting that PIK3CA mutation is clonal;
whereas there is heterogeneous expression of AR within
the cell line.
To determine the relative sensitivity of AR + versus AR-
TNBC cell lines to PI3K pathway inhibitors, we treated a
large panel of cell lines with the pan-PI3K inhibitors
GDC-0941 and NVP-BKM120 or with the dual PI3K/
mTOR inhibitors GDC-0980 and NVP-BEZ235. AR + cell
lines (indicated in green, Figure 3) and other TNBC cell
lines containing PIK3CA mutations (indicated in red,
Figure 3) were the most sensitive to pharmacological PI3K
inhibition, as indicated by low, half-maximal inhibitory
concentration (EC50) values. AR + TNBC cells were sig-
nificantly more sensitive to GDC-0941 (680 nM versus
2044 nM, P = 0.01) and GDC-0980 (66 nM versus 504
nM, P = 0.015) compared to the other cell lines. In con-
trast, cell lines with PTEN deficiency, while displaying ele-
vated PI3K pathway signaling, did not uniformly have
increased sensitivity to PI3K inhibitors (Figure 3). Al-
though AR + TNBC cells displayed sensitivity to NVP-
BKM120 and NVP-BEZ235, we chose to highlight the re-
sults from GDC-0941 and GDC-0980 in the figures that
follow with the results from NVP-BKM120 and NVP-
BEZ235 included as Additional file 8: supplemental data.Genetic or pharmacologic inhibition of AR increases
sensitivity to PI3K pathway inhibitors
Since the LAR TNBC cell lines that are sensitive to AR
antagonists also harbor highly clonal PIK3CA mutations
and are sensitive to PI3K inhibitors [3], we hypothesized
that combined targeting of AR and PI3K would more
effectively induce growth arrest or apoptosis than either
agent alone. To test this hypothesis, we performed both
genetic knockdown and pharmacological inhibition of
AR with shRNA and CDX, respectively, in the presence
and absence of PI3K pathway inhibitors. Immunoblot
analysis confirmed decreased AR protein levels in all
four AR-expressing TNBC cell lines infected with lenti-
virus containing two AR-targeting hairpins (shAR-1 and
shAR-2) relative to those expressing control, non-
targeting shRNA (Figure 4A). Both shRNA expression
vectors targeting AR decreased cell viability alone and
across increasing doses of GDC-0941 and GDC-0980
(Figure 4B). The most significant difference in viability
was observed in cell lines (CAL-148 and MDA-MB-
453), where the greatest knockdown of AR was achieved.
Similar results were obtained with NVP-BKM-120 and
NVP-BEZ235, further suggesting that the results observed
were specific to inhibition of the PI3K pathway and not
off-target drug effects (Additional file 9: Figure S6).
Given that knockdown of AR had an additive antitu-
mor effect with PI3K inhibitors, we pharmacologically
inhibited AR using the AR antagonist CDX. Treatment
with either GDC-0941 or GDC-0980 decreased prolifer-
ation/survival in a dose-dependent manner in AR +
TNBC cell lines; the addition of 25 μM CDX shifted the
survival curves to or below the predicted line of additiv-
ity calculated from the effect of each agent alone
(Figure 5A). We observed the greatest degree of synergy
with the two classes of drugs in cell lines in which CDX
was less effective alone (MFM-223) as demonstrated by
dose-response curves below the line of additivity
(Figure 5A). In contrast, we only observed an additive
inhibitory effect when the AR antagonist was used in
combination with PI3K inhibitors in cell lines that were
more sensitive to single agent CDX (CAL148, MDA-
MB-453 and SUM185) (Figure 5A).
To verify that the PI3K inhibitors were hitting the
target, we performed immunoblot analyses on lysates
harvested from control cultures or cells treated alone or
in combination with CDX (25 μM), GDC-0941 (300 nM)
and GDC-0980 (100 nM). Treatment with GDC-0941 and
GDC-0980 decreased AKT activity as assessed by levels of
phosphorylated AKT (p-S473). As anticipated, GDC-0980
was more effective at decreasing mTOR activity, measured
by the decrease in levels of phosphorylated S6 (Figure 5B).
In contrast, CDX treatment alone had minimal effect on
either the PI3K/mTOR pathway or AR levels. Interest-
ingly, GDC-0980 treatment alone decreased AR levels and
Figure 3 Androgen receptor (AR) + triple-negative breast cancer (TNBC) cell lines are sensitive to PI3K inhibitors. Bar graphs show the
50% inhibitory concentration (EC50) for TNBC cell lines treated for 72 h with single-agent (A) pan PI3K inhibitors (GDC-0941 and (B) NVP-BKM-120) or
dual PI3K/mTOR inhibitors (GDC-0980 and NVP-BEZ235). Black horizontal bars above graphs indicate cell lines in which the EC50 was not reached at
maximal concentration. Colorbar below indicates primary human mammary epithelial cell (HMECs) (black), AR + cell lines (green) and cell lines with
PIK3CA mutations (red) or PTEN loss (blue). Error bars represent SD for three independent infections and experiments.
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CDX, suggesting that mTOR activity may contribute to
elevated AR protein levels (Figure 5B), similar to the sig-
naling observed in prostate cancer [13]. Similar results
were obtained with NVP-BKM-120 and NVP-BEZ-235
(Additional file 10: Figure S7).
To determine if the observed decrease in cell number
in the AR + TNBC cultures, which were treated with the
combination of pathway inhibitors, was attributable to
apoptotic cell death, we measured activated caspase-3
and caspase-7 levels after drug treatments (Additional
file 11: Figure S8). As a positive control, we prepared ly-
sates from cells treated with adriamycin (ADR, 3 μM)
and observed caspase activation at 48 h (Additional
file 11: Figure S8). While CDX treatment alone did not
elevate caspase activity, treatment with single agent GDC-
0941 and GDC-0980 elevated levels of cleaved caspase-3
and -7 with the levels increasing 1.2 to 2-fold whenPI3K inhibitors were used in combination with CDX
(Additional file 11: Figure S8A).
In addition to caspase activity, we quantified the per-
centage of sub 2 N DNA (sub-G1)-containing cells by
FACS analysis (indicative of late stage apoptotic DNA
fragmentation). In contrast to the absence of caspase
cleavage describe above, CDX treatment alone led to an
elevation in the sub-G1 fraction 48 h after treatment
(Additional file 11: Figure S8B). Treatment with GDC-
0941 or GDC-0980 resulted in higher sub-G1 fraction
that increased after combination treatment with CDX
(average increase 6.0% for GDC-0941 and 17.1% for
GDC-0980) (Additional file 11: Figure S8B and C), con-
cordant with the elevated caspase activity observed in
Additional file 11: Figure S8A. Therefore, the decreased
viability of AR +TNBC cell lines treated with a combin-
ation of AR and PI3K inhibitors can be, in part, attributed
to increased apoptosis.
Figure 4 Genetic targeting of androgen receptor (AR) is additive in combination with PI3K inhibition. (A) Immunoblot shows AR protein
levels at 72 h following transduction with two shRNAs targeting AR (shAR-1 and shAR-2) compared to transduction with nontargeting shRNA
(shNT) in the indicated AR + triple-negative breast cancer (TNBC) cell lines. Actin levels are shown for the loading control. (B) Line graphs display
relative viability of AR + cell lines transduced with nontargeting (shNT) or shRNAs targeting AR (shAR-1 and shAR-2) after 72 h treatment with
increasing concentrations of the pan-PI3K inhibitor GDC-0941 (top) or the dual PI3K/mTOR inhibitor GDC-0980. Error bars represent SD for three
independent infections.
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decreases viability of AR-expressing cell lines grown in
the absence of adhesion
As cell viability and drug sensitivity can be different in
2-dimensional versus 3-dimensional growth conditions,
we evaluated combined targeting of AR and PI3K in a
forced-suspension assay devoid of matrix. Cell lines grown
in suspension were treated with GDC-0941 or GDC0980
alone or in combination with CDX (Figure 6). The addition
of CDX was either additive or synergistic with PI3K in-
hibition (Figure 6B). Similar results were obtained when
PI3K was inhibited with NVP-BKM120 or NVP-BEZ235
(Additional file 12: Figure S9). However, when comparing
3-dimensional (Figure 6B) to 2-dimensional growth, we
observed that viability was greater by approximately 2-fold
across all doses in the 3-dimensional cultures on average.
The results suggest that simultaneous targeting of AR andPI3K signaling pathways is more effective than targeting
either pathway alone in AR + TNBC in monolayer or
absence of adhesion in a forced suspension assay.
Simultaneous targeting of AR and PI3K signaling
decreases the growth of LAR cell line-derived xenograft
tumors in athymic mice
Based on the results from 2-dimensional and 3-dimen-
sional cell culture models, we investigated the effect of
combined targeting of AR and PI3K in vivo in LAR cell
line-derived tumor xenografts. We established MDA-MB-
453 and CAL-148 tumors in athymic nude mice. When tu-
mors reached approximately 50 mm3 in size, the mice were
either treated with vehicle, CDX (100 mg/kg/d), GDC-
0941 (50 mg/kg/d), or GDC-0980 (7.5 mg/kg/d) alone or
in combinations for 13 to 21 days depending on growth
rate of the cell line. Although CDX alone did not
Figure 5 Pharmacological targeting of androgen receptor (AR) with bicalutamide (CDX) is additive in combination with of GDC0941
and GDC0980 in AR + triple-negative breast cancer (TNBC) cell lines. (A) Line graphs show viability of AR + cell lines treated with increasing
concentrations of GDC-0941 (top) or GDC-0980 (bottom) alone (blue) or in combination (red) with 25 μM CDX. Dashed black line depicts the
theoretical line of additivity of both drugs determined from the effect of CDX alone and either GDC-0941 or GDC-0980 alone. Error bars represent
SD for three independent experiments. (B) Immunoblots from AR + TNBC cell lines treated with either CDX (25 μM), GDC-0941 (300 nM) or GDC0980
(100 nM) as single agents or CDX in combination with either GDC-0941 or GDC-0980 for 48 h analyzed for AR, p-AKT, AKT, p-S6, S6 and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) protein.
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both MDA-MD-453 (319 versus 215 mm3, P = 0.047)
and CAL-148 (1394 versus 540 mm3, P = 0.063) xeno-
graft tumors (Figure 6C). Both single agents GDC-0941
and GDC-0980 significantly reduced tumor growth of
MDA-MD-453 (319 mm3 versus 199 mm3 and 57 mm3 re-
spectively, P = 0.0001) and CAL-148 (1394 mm3 versus
388 mm3 and 171 mm3 respectively, P = 0.050 and P =
0.004) (Figure 6C). Since the PI3K inhibitors were very
effective alone, the added benefit of CDX was difficult to
evaluate. However, the combination of CDX with GDC-
0941 significantly decreased the volume of MDA-MB-453
xenograft tumors (149 mm3 versus 36 mm3, P = 0.003)and CDX in combination with GDC0980 significantly
decreased growth (171 mm3 versus 97 mm3, P = 0.041) of
CAL-148 xenograft tumors compared to single agent
PI3K inhibition (Figure 6C). GDC-0980 alone or in com-
bination with CDX reduced tumor growth more than
GDC-0941, suggesting that concomitant targeting of
mTOR provides additional therapeutic benefit or alterna-
tively that the pharmacodynamics of the dosing protocol
was superior for GDC-0980.
Discussion
Herein, we show that activating kinase mutations in
PIK3CA are a frequent event in a subset of AR + TNBC
Figure 6 Simultaneous pharmacological targeting of androgen receptor (AR) and PI3K decreases viability of AR + triple-negative breast
cancer (TNBC) cell lines grown in 3-dimensional suspension culture or in vivo as xenograft tumors. (A) Bright field images display
3-dimensional cell aggregates of MDA-MB-453 cells treated with increasing doses of GDC-0941 or GDC-0980 in the absence or presence of CDX
(25 μM). (B) Line graphs display relative viability of 3-dimensional cell aggregates treated with GDC-0941 or GDC-0980 alone (blue) or in combination
(red) with 25 μM bicalutamide (CDX). Dashed black line depicts the theoretical line of additivity determined from the effect of CDX alone and either
GDC-0941 or GDC-0980 alone. (C) Athymic nude mice bearing established xenograft tumors from AR + TNBC cell lines (MDA-MB-453 and CAL-148)
were divided into equal cohorts (n = 8) treated with either CDX (100 mg/kg/d, black hashed line), GDC-0941 (100 mg/kg/d, blue line), GDC-0980
(7.5 mg/kg/d red line) or with the combination of CDX and either GDC0-0941 (blue hashed line) or GDC-0980 (red hashed line). Serial-tumor volumes
(mm3) were measured at the indicated days. Each data point represents mean tumor volume of 16 tumors; error bars represent standard error of
the mean.
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pathway and AR signaling was previously established in
prostate cancer [14] and PIK3CA mutations are enriched
in ER + breast cancer [7]. We demonstrate that not only
are PIK3CA mutations predominant in AR + TNBC, butthat they are co-selected with amplification of the
PIK3CA locus. Concurrent amplifications and mutations
in PIK3CA have previously been reported in uterine
serous carcinoma [15], in uterine corpus endometriod
cancer (9 of 17 amplified, 53%), head and neck squamous
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carcinoma (10 of 67 amplified, 15%), and breast cancer (16
of 37 amplified, 43%) [16,17]. The co-occurrence of am-
plification and mutation for PIK3CA is far more frequent
than for other known oncogenes (BRAF, KRAS, ERBB2), in
which mutations and amplifications tend to be mutually ex-
clusive. This finding suggests that a higher level of PIK3CA
activity may be needed to overcome a negative regulatory
mechanism or that one or more genes in the 3q26 ampli-
con containing PIK3CA are functionally important.
Mechanistic insights to the evolution of hormone-
dependent tumors with deregulated PI3K signaling were
first provided by Carver et al., who demonstrated that
inhibition of AR activates AKT signaling by reducing
levels of the AKT phosphatase PHLPP in prostate cancer
cells [14]. A recent siRNA screen identified AKT1 as a
target that impaired the growth of AR + prostate cancer
cell lines, consistent with the PI3K pathway playing an
essential role in survival of AR-dependent cells [18]. Inter-
estingly, while AR has been shown to directly inhibit
PTEN transcription in prostate cancer cells [14], AR has
been reported to activate PTEN transcription in breast can-
cer cells [19]. If the latter were the case, elevated PIK3CA
protein activity (through mutation and amplification) in
AR +TNBC tumors would provide a mechanism to bypass
the AR-mediated upregulation of PTEN. Therefore, target-
ing AR alone could potentially promote survival by redu-
cing PTEN expression and activating the PI3K pathway.
Thus, our working hypothesis is that dual targeting of PI3K
and AR will provide a synergistic anti-tumor effect.
We and others have shown that approximately 10 to
20% of TNBCs express AR [3,20]. In addition, Farmer
and colleagues have previously identified a distinct gene
expression pattern in ER-, AR + breast cancers termed
molecular apocrine representing 8 to 14% of all breast
cancers [21]. Clinically, AR-negative patients have a higher
likelihood of achieving pathological complete response
(pCR) with neoadjuvant chemotherapy than AR + patients
[22]. In addition, Masuda et al. recently completed a re-
trospective TNBC subtype analysis of gene expression per-
formed on 130 pretreatment biopsies from TNBC patients
treated with anthracycline, cytoxan and taxane. While the
overall pCR response was 28%, patients with the LAR
subtype had a poor response with only 10% achieving pCR
prior to surgery [23]. These findings and the observation
that AR + TNBC cell lines are relatively resistant to
cisplatin [3], suggest TNBC patients with AR + tumors
will not receive significant clinical benefit from standard
chemotherapy and require novel targeted approaches.
An ongoing clinical trial evaluating CDX as a single agent
in metastatic AR+, ER-/PR- breast cancers (NCT00468715/
TBCRC011) has demonstrated some efficacy with a clinical
benefit rate of 19% [24]. While combined inhibition of AR
and the PI3K pathway has yet to be carried out in clinicaltrials, combinations of PI3K inhibitors with the ER down-
regulator, fulvestrant, are now underway in postmeno-
pausal patients with ER+/HER2- stage IV breast cancer
who have progressed on aromatase inhibitors (BELLE-2,
NCT01339442) or on the TORC1 inhibitor everolimus
(BELLE-3, NCT01633060) [25].
Conclusions
The results of our study have immediate translational im-
plications for the treatment of AR + TNBC. AR expression
is already a robust biomarker with an existing CLIA-
approved diagnostic platform that is used in the clinical
setting. From published studies, it is apparent that patients
with AR + TNBC tumors are likely to demonstrate limited
benefit from the current standard-of-care chemotherapy
regimens for TNBC [22,23]. Thus, our pre-clinical data
inform the design of a combination therapy that would be,
to our knowledge, the first trial in which TNBC patients
are divided based on a biomarker (AR expression) and, as
a result, aligned to a targeted investigational combination
treatment.
Additional files
Additional file 1: Table S1. Triple-negative breast cancer (TNBC)
molecular subtyping of The Cancer Genome Atlas (TCGA). Table displays
TCGA patient barcode with TNBC subtype with clinical parameters
(estrogen receptor (ER), progesterone receptor (PR), human epithelial
growth factor receptor 2 (HER2) immunohistochemistry (IHC), HER2
fluorescent in-situ hybridization (FISH), and age) and corresponding
androgen receptor (AR) protein and mRNA levels and PIK3CA mutation
status.
Additional file 2: Figure S1. PIK3CA mutations have a high clonal
frequency in androgen receptor (AR) + triple-negative breast cancer
(TNBC) tumors. (A) Panels display the frequency of PIK3CA mutations
(H1047R) in both DNA and RNA sequencing reads from the same tumor
(The Cancer Genome Atlas (TCGA)-CE-A12L). (B) Panels display RNA
sequencing reads from two additional AR + TNBC tumors with PIK3CA
mutations.
Additional file 3: Figure S2. Frequent concurrent amplification and
mutation of PIK3CA in human breast cancers. Image displays 43 tumors
with overlapping amplicons of PIK3CA (>4 copies) from The Cancer
Genome Atlas (TCGA) breast cohort. Vertical color bars indicate androgen
receptor (AR) + triple-negative breast cancer (TNBC) (green) and tumors
in which PIK3CA is also mutated (blue).
Additional file 4: Table S2. Linear normalized median-centered (log2)
reverse-phase protein array (RPPA) values for triple-negative breast cancer
(TNBC) cell lines. Table shows median-centered RPPA values for 179 proteins
for each of the cell lines, performed in duplicate.
Additional file 5: Figure S3. Triple-negative breast cancer (TNBC) cell
lines express both androgen receptor (AR) and p-AKT by immunofluorescence.
Immunofluorescent images of MFM-223 (top) and SUM-185 (bottom)
co-stained for AR (red), p-AKT(S473) (green) and counterstained with
DAPI (blue). Altered cellular morphology is due to cytospin preparation.
Additional file 6: Figure S4. Triple-negative breast cancer (TNBC) cell lines
express both androgen receptor (AR) and p-AKT by immunofluorescence.
Immunofluorescent images of MDA-MB-453 (top) and CAL-148 (bottom)
co-stained for AR (red), p-AKT(S473) (green) and counterstained with DAPI
(blue). Arrows indicate a percentage of AR- cells that stain positive for p-AKT.
Additional file 7: Figure S5. PIK3CA mutation in CAL-148 cells is
present in both androgen receptor (AR) + and AR- cells sorted by
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http://breast-cancer-research.com/content/16/1/406fluorescence-activated cell sorting (FACS). (A) FACS scattergrams for AR +
triple-negative breast cancer (TNBC) cell lines incubated with alexa fluor
488 secondary antibody alone (control, top panels) or with anti-AR
antibody (bottom panels). (B) CAL-148 cells were flow sorted into ARlow
(bottom 20%) and ARhigh (top 20%) populations in which DNA was
isolated and PIK3CA evaluated by Sanger sequencing.
Additional file 8: Supplemental methods.
Additional file 9: Figure S6. shRNA targeting of androgen receptor
(AR) is additive in combination with PI3K inhibitors. Line graphs display
relative viability of luminal androgen receptor (LAR) cell lines transduced
with nontargeting (shNT) or shRNAs targeting AR (shAR-1 and shAR-2)
after 72 h treatment with the pan-PI3K inhibitor NVP-BKM-120 (top) or
the dual PI3K/mTOR inhibitor NVP-BEZ235 (bottom). Data represent the
average of three replicates.
Additional file 10: Figure S7. Pharmacological targeting of androgen
receptor (AR) with bicalutamide (CDX) is additive in combination with
PI3K inhibitors in AR + triple-negative breast cancer (TNBC). (A) Line
graphs show relative viability of AR-expressing cell lines treated with an
increasing concentration of BKM120 (top) or NVP-BEZ235 (bottom) as
single agents (blue) or in combination (red) with CDX (25 μM). Dashed
black line depicts the theoretical line of additivity determined from the
effect of CDX alone and either BKM120 or NVP-BEZ235 alone. Error bars
represent SD for three independent experiments. (B) Immunoblots from
AR-expressing TNBC cell lines treated with either CDX, BKM120 (1 μM),
NVP-BEZ235 (100 nM) alone or CDX in combination with either BKM120
or NVP-BEZ235 for 24 h or 48 h analyzed for AR, p-AKT, AKT, p-S6, S6 and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein.
Additional file 11: Figure S8. Combined inhibition of androgen
receptor (AR) and PI3K increases apoptotic cell death in AR + triple-
negative breast cancer (TNBC) cell lines. (A) Bar graphs display relative
caspase 3/7 activity (RLU) normalized to viable cell number 48 h after
treatment with vehicle, positive control (3 μM ADR), bicalutamide (CDX)
(50 μM), GDC-0941 (3 μM) or GDC-0980 (1 μM) as single agents or in
combination with CDX. Error bars represent SD for three independent
experiments. (B) Representative cell cycle histograms of the MDA-MB-453
cell line treated with similar conditions as described above. (C) Bar graphs
indicate percentages of sub-G1 DNA, indicative of late-stage apoptotic
DNA fragmentation.
Additional file 12: Figure S9. Simultaneous targeting of androgen
receptor (AR) and PI3K decreases viability of AR + triple-negative breast
cancer (TNBC) cell lines grown in a 3-D forced suspension assay. Line
graphs display relative viability of 3-D cell aggregates treated with
BKM120 (top) or NVP-BEZ235 (bottom) as single agents (blue) or in
combination (red) with CDX (25 μM). Dashed black line depicts the
theoretical line of additivity determined from the effect of bicalutamide
(CDX) alone and either BKM120 or NVP-BEZ235 alone. Error bars represent
SD for three independent experiments.Abbreviations
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